Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.36 |
| ▸ | BCHE | P06276 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 4/20 | 0.35 |
| ▸ | PPARA | Q07869 | 4/20 | 0.35 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL650072 | 0.92 | C5AR1 (0.41) | TLR7BCHEMAPTC5AR1ALDH1A1 | |
| SCHEMBL649822 | 0.91 | C5AR1 (0.39) | TLR7BCHEMAPTC5AR1ALDH1A1 | |
| SCHEMBL650050 | 0.91 | MAPT (0.39) | TLR7BCHEMAPTC5AR1ALDH1A1 | |
| SCHEMBL650991 | 0.91 | TLR7 (0.38) | TLR7BCHEMAPTC5AR1ALDH1A1 | |
| SCHEMBL648391 | 0.91 | C5AR1 (0.38) | TLR7BCHEMAPTC5AR1ALDH1A1 | |
| SCHEMBL1913031 | 0.91 | TSHR (0.40) | TLR7MAPTC5AR1ALDH1A1HTT | |
| SCHEMBL651129 | 0.91 | MAPT (0.42) | TLR7BCHEMAPTC5AR1ALDH1A1 | |
| SCHEMBL649888 | 0.91 | C5AR1 (0.40) | BCHEMAPTC5AR1ALDH1A1HTT | |
| SCHEMBL647849 | 0.90 | CRHR1 (0.38) | BCHEMAPTC5AR1ALDH1A1HTT | |
| SCHEMBL652368 | 0.89 | C5AR1 (0.39) | BCHEMAPTC5AR1ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119667-B2 | Carbonates of fenicol antibiotics | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2012-02-21 | — | — | US | claimed |
| EP-1966129-B1 | CARBONATES OF FENICOL ANTIBIOTICS | SCHERING PLOUGH LTD (CH) | 2011-08-17 | — | — | EP | claimed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-8119667-B2 | Carbonates of fenicol antibiotics | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (US) | 2012-02-21 | — | — | US | disclosed |
| EP-1966129-B1 | CARBONATES OF FENICOL ANTIBIOTICS | SCHERING PLOUGH LTD (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20070155799-A1 | CARBONATES OF FENICOL ANTIBIOTICS | INTERVET INC. | 2007-07-05 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155799-A1 | CARBONATES OF FENICOL ANTIBIOTICS | CYP4F3, TET1, CYP4F2 | TLR7 628/4885BCHE 1717/4885MAPT 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.